Who are Simvastatin plus ticagrelor's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rosuvastatin plus clopidogrel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/simvastatin-plus-ticagrelor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Simvastatin plus ticagrelor — Competitive Intelligence Brief

Simvastatin plus ticagrelor (Simvastatin plus ticagrelor) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Statin plus P2Y12 receptor antagonist combination. Area: Cardiovascular.

marketed Statin plus P2Y12 receptor antagonist combination HMG-CoA reductase; P2Y12 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Simvastatin plus ticagrelor (Simvastatin plus ticagrelor) — Federal University of São Paulo. Simvastatin reduces cholesterol synthesis while ticagrelor inhibits platelet aggregation, combining lipid-lowering and antiplatelet effects for cardiovascular protection.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Simvastatin plus ticagrelor TARGET	Simvastatin plus ticagrelor	Federal University of São Paulo	marketed	Statin plus P2Y12 receptor antagonist combination	HMG-CoA reductase; P2Y12 receptor
Rosuvastatin plus clopidogrel	Rosuvastatin plus clopidogrel	Federal University of São Paulo	marketed	Statin plus antiplatelet agent combination	HMG-CoA reductase; P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Statin plus P2Y12 receptor antagonist combination class)

Federal University of São Paulo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Simvastatin plus ticagrelor — Competitive Intelligence Brief. https://druglandscape.com/ci/simvastatin-plus-ticagrelor. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab